Gilead Sciences patent for toll-like receptor modulator compounds

USPTO granted Patent No. US12590089B2 to Gilead Sciences, Inc. on March 31, 2026. The patent covers processes for preparing toll-like receptor (TLR) modulator compounds, specifically (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or salts thereof and related key intermediates. The patent names 12 inventors and contains 7 claims under CPC classifications including C07D 471/04 and A61K 31/519.\n\nThis is a standard patent grant notification with no compliance requirements or deadlines for other parties. Competitors developing TLR modulator compounds should review this patent to assess potential freedom-to-operate implications. No action is required from compliance teams unless conducting R&D in this specific chemical space.